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Neuregulin-erbB signalling promotes microglial proliferation and
chemotaxis contributing to microgliosis and pain following
peripheral nerve injury
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1 Wolfson CARD, Kings College London, UK
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Abstract
A key component in the response of the nervous system to injury is the proliferation and switch to
a ‘pro-inflammatory’ phenotype by microglia (microgliosis). In situations where the blood brain
barrier is intact microglial numbers increase via the proliferation and chemotaxis of resident
microglia, however there is limited knowledge regarding the factors mediating this response.
Following peripheral nerve injury a dorsal horn microgliosis develops which directly contributes
to the development of neuropathic pain. Neuregulin-1 is a growth and differentiation factor with a
well characterised role in neural and cardiac development. Microglia, express the NRG1 receptors
erbB 2, 3 and 4 and NRG1 signalling via the erbB2 receptor stimulated microglial proliferation,
chemotaxis, survival as well as interleukin-1β release in vitro. Intrathecal treatment with NRG1
resulted in microglial proliferation within the dorsal horn and these cells developed an activated
morphology. This microglial response was associated with the development of both mechanical
and cold pain related hypersensitivity. Primary afferents express NRG1 and following spinal nerve
ligation (SNL) we observed both an increase in NRG1 within the dorsal horn as well as activation
of erbB2 specifically within microglia. Blockade of the erbB2 receptor or sequestration of
endogenous NRG following SNL reduced the proliferation, the number of microglia with an
activated morphology and the expression of phospho-P38 by microglia. Furthermore consequent
on such changes the mechanical pain related hypersensitivity and cold allodynia were reduced.
NRG1-erbB signalling therefore represents a novel pathway regulating the injury response of
microglia.
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Microglia, are the resident myeloid cells of the CNS and respond rapidly to injury of the
nervous system. This injury response (or ‘microgliosis’) has a number of different
components including: microglial cell proliferation (Ajami et al., 2007;Echeverry et al.,
2008), migration to the site of injury (Ifuku et al., 2007;Honda et al., 2001;Yao et al.,
1990;Peterson et al., 1997), phagocytosis of cellular debris (Neumann et al., 2009), antigen
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presentation (Fischer and Reichmann, 2001), adoption of an amoeboid morphology, and the
release of a broad range of cytokines and chemokines (Milligan and Watkins, 2009).
Microglia express receptors for and respond to a range of injury related molecules including
cytokines, chemokines, complement components and purines. These molecules regulate
different components of the injury response (a process which can be thought of as a
continuum rather than an ‘all or nothing event’). The microglial response to peripheral nerve
injury contributes to the generation of neuropathic pain and these cells are also implicated in
disease processes as diverse as traumatic brain injury, neurodegeneration and demyelination
(Hanisch and Kettenmann, 2007; Scholz and Woolf, 2007; Ransohoff and Perry, 2009). It
has recently been demonstrated using chimeric animals obtained by parabiosis or bone
marrow transplantation and selective irradiation that in situations where the blood brain
barrier is intact the principal means by which microglial numbers increase is through the
proliferation of resident microglia (rather than recruitment of blood born bone marrow
derived microglial progenitors) (Ajami et al., 2007; Mildner et al., 2007). In this study we
focus on the role of NRG1 in modulating microglial proliferation chemotaxis and cytokine
release.
Neuregulin 1 (NRG1) is one of a family of growth factors (NRG1-4). NRG1 undergoes
alternative splicing and differential promoter use to produce at least 15 isoforms which
include both secreted and transmembrane forms (Esper et al., 2006; Falls, 2003). NRG1 has
a key role in neural and cardiac development (Lee et al., 1995), it can modulate synaptic
plasticity (Mei and Xiong, 2008) and it can stimulate the proliferation, survival and motility
of a number of different cell types (Falls, 2003). All NRG1 isoforms contain an Epidermal
Growth Factor (EGF)-like domain which is critical for mediating biologic activity and
which binds to the tyrosine kinase receptors erbB3 and 4. These receptors subsequently
heterodimerize with erbB2, which lacks a ligand binding domain but which is a key co-
receptor in mediating signal transduction (Carraway, III and Cantley, 1994). ErbB3 lacks an
active tyrosine kinase domain and so its interaction with erbB2 is essential for signalling.
ErbB4 can signal via homodimers but dimerizes preferentially with erbB2 (Graus-Porta et
al., 1997). Microglia are reported to express erbB 2, 3 and 4 receptors (Gerecke et al., 2001;
Dimayuga et al., 2003)–however very little is known regarding the function of this signaling
pathway within microglia. We therefore studied the effects of NRG1 on microglial survival,
proliferation, chemotaxis and cytokine release in vitro and subsequently tested the
hypothesis that this signalling pathway contributes to microgliosis and neuropathic pain
following peripheral nerve injury in vivo.
Experimental procedures
Animals and surgery
Adult male Wistar rats were used in accordance with UK Home Office regulations. In one
group of animals the left L5 spinal nerve was ligated and transected. Sham-operated animals
were prepared in an identical manner but without injuring the nerve. To label dividing cells,
rats were injected with 5-Bromo-2′-deoxyuridine (BrdU; Sigma dissolved in 0.007N NaOH/
PBS, 100 mg/kg body weight i.p.) once daily for 3 consecutive days before perfusion and
fixation.
Drugs and delivery
PD 168393 (Calbiochem) an irreversible erbB inhibitor was dissolved in 5% DMSO and
delivered intrathecally at 1.25, 2.5, 5 or 10 μg/day by an Alzet osmotic pump (Cupertino,
Model 2002). Control animals were given the same vehicle solution lacking the active
compound. Anti-erbB2 antibodies (mAb 7.16.4 from Calbiochem and mAb-9 from Thermo
Scientific, without Azide) were delivered intrathecally via lumbar puncture one hour before
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nerve injury (2.5, 5 or 10 μg diluted in 25uL sterile PBS). For perineural application of
mAB 7.16.4 to the site of nerve injury a 0.5 × 0.5 cm strip of oxidized regenerated cellulose
(Surgicell, Ethicon) soaked in 10 μg of the antibody diluted in sterile PBS was applied
directly over the site of spinal nerve ligation. Control animals received a non immune IgG2a
antibody (Calbiochem) via the same method (i.t. or perineural respectively). To sequester
endogenous NRG we used a fusion protein (HBD-S-H4) that was injected i.t every 3 days (3
μg in 20μl of sterile saline per injection). The drug doses were selected on the basis of
previous reports and our preliminary studies. Neuregulin β1 EGF domain (rHRGβ1
aa177-244) was administered i.t. via lumbar puncture (0.4 or 4 ng in a volume of 20μl). To
label dividing cells post NRG1 treatment, rats were injected with 5-Bromo-2′-deoxyuridine
(BrdU; Sigma dissolved in 0.007N NaOH/PBS, 100 mg/kg body weight i.p.) 24 hr before
perfusion and fixation. Before surgery animals were randomly allocated into experimental
study groups (computer-generated randomization schedules). An independent investigator
prepared the drugs individually and labelled them for each animal according to the
randomization schedule. Operators and data analysts were blinded throughout the study.
Behavioural testing
Mechanical withdrawal thresholds were tested using a Dynamic Plantar Aesthesiometer
(Ugo Basile, Italy) which is an automated version of the von Frey hair assessment. A
maximum cut-off of 50g was used. The withdrawal threshold is calculated as the average of
three consecutive tests with at least 10 minutes between each test. To measure cold
allodynia, we applied a drop of acetone to the plantar hindpaw and measured the time that
the animal spent licking, shaking, or lifting the paw during the following 2 min (Kontinen
and Dickenson, 2000).
Histology
After defined survival times, animals were terminally anaesthetized and transcardially
perfused with 4% paraformaldehyde plus 1.5% picric acid in 0.1M phosphate buffer. The
lumbar spinal cords and L5 dorsal root ganglia were excised, cryoprotected in 20% sucrose,
cryostat cut (10 or 20 μm) and thaw-mounted onto glass slides. Spinal cord sections were
incubated overnight with the primary antibody: rabbit anti-phospho-p38MAPK (1:100, Cell
Signalling) or rabbit anti-phospho-erbB2 (p-Neu (Tyr 1248), 1:200, Santa Cruz BT), both of
which were viewed by tyramide amplification (TSA™ Biotin System, Perkin Elmer) or with
anti-rabbit Neuregulin-1 (H-210), Polyclonal Antibody (1:100, Santa Cruz Biotechnology).
For co-localization studies the slides were then incubated with rabbit anti-Iba1 (1:1000,
WAKO), mouse anti-OX42 (1:200, Serotec), rabbit anti-GFAP (1:1000, Dako), or mouse
anti-NeuN (1:1000, Chemicon). DRGs sections were incubated overnight with the calcitonin
gene-related peptide antibody (rabbit anti-CGRP, 1:2000, Sigma) and neurofilament 200
antibody (mouse anti-NF200, 1:1000, Chemicon, UK) or with anti-rabbit Neuregulin-1
(H-210). Following primary antibody incubation sections were washed and incubated for 1.5
h with corresponding secondary antibody solution. Isolectin B4 (IB4) detection was carried
out using biotin-conjugated IB4 (Sigma, 1:50) and ExAvidin-AMCA (1:400, Vector Labs,
UK). Slides were washed, cover-slipped with Vectashield mounting medium with or without
DAPI (Vector Laboratories) and visualised under a Zeiss Axioplan 2 fluorescent microscope
(Zeiss, U.K). The specificity of immunostaining was checked by the omission of the
appropriate primary antibody or pre-incubation with the corresponding blocking peptide.
Antibody detection of BrdU incorporated into DNA requires pre-treatment of the tissue to
expose the BrdU epitope. For this purpose we used the antigen retrieval method described
previously (Tang et al., 2007). Primary antibody solution contained mouse anti BrdU (1:200,
BD:Biosciences) plus rabbit anti Iba-1 (1:1000, Wako) and the Secondary Antibody solution
contained corresponding IgG-conjugated FITC 1:200 plus IgG-conjugated Cy3 1:400 (both
from Stratech, UK).
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Microglia cells and macrophages were 4%PFA fixed for immunohistochemistry. Microglia
were double stained with erbB receptors antibodies (erbB 2 /Neu(C-18), erbB3 (C-17) and
erbB4(C-18) rabbit, 1:100, Santa Cruz BT) and Isolectin B4 biotin conjugated (to label
microglia, 1:50 Sigma) and visualized with corresponding secondary antibodies (Cy3 1:400
Stratech, UK for erbB receptors, extra-avidin FITC 1:200 Sigma, for IB4). For detecting
MHC class II we used the monoclonal mouse anti-rat RT1B (clone OX-6) antibody from
Serotec, UK (1:100). We used the ApopTag Fluorescein In Situ kit (Chemicon, USA) to
identify apoptotic nuclei by terminal deoxynucleotidyl transferase-mediated X-dUTP nick
end labelling (TUNEL). Macrophages and microglial cultures purity was assessed staining
cells with Iba1 and DAPI.
In Situ hybridization
ISH was performed after immunohistochemistry using 34-nucleotide long probes as
previously described (Michael et al., 1997) The sequence and specificity of the NRG1 probe
has been described before (Fricker et al., 2009) Oligonucleotides were chemically
synthesized (Sigma-Genosys, UK) and radioactively end-labelled with 35S-dATP (Perkin-
Elmer Life Sciences, Boston, MA, USA) using terminal deoxynucleotidyl transferase
(Promega). Following pre-hybridization treatments (acetylation, dehydration, delipidation),
the radioactive probe was added on the sections and hybridization was performed overnight
at 37°C. The next day slides were washed in standard saline citrate solutions with increasing
stringencies, rapidly dehydrated through graded alcohols, air-dried, dipped in
autoradiographic emulsion (LM1, GE Healthcare, UK) and developed for 3–4 weeks.
Quantification and analysis
Quantitative assessment was carried out by determining the numbers of immunoreactive
cells within 4 areas of 10,000 μm2 in the superficial dorsal horn on 5-7 randomly selected
L5 spinal sections from each animal. For BrdU staining the whole dorsal horn was analyzed.
Microglia in which process length was less than double the soma diameter were classified as
presenting an activated (or effector) morphology. Microglia in which the process length was
double the soma diameter were classified as resting (or surveying) cells (Stence et al., 2001)
(Figure 7). Cells were sampled only if the nucleus was visible within the plane of section
and if cells profiles exhibited distinctly delineated borders. For quantification of dorsal root
ganglia ISH, cells exhibiting grain density twice background levels were counted as
exhibiting a positive hybridization signal. All analysis were performed with the operator
blinded to treatment groups.
Detection of NRG1-β1 by ELISA
Ipsilateral dorsal horns were homogenized in lysate buffer (20 mM Tris, pH 8, 137 mM
NaCl, 1% NP-40, 1 mM sodium orthovanadate, and protease inhibitor cocktail) and NRG1
was detected from lysates using a NRG1-β1 specific ELISA kit (detection range: 250-40000
pg/mL, DuoSet ELISA DY377, R&D Systems, UK). NRG1-β1 standards (250-40000 pg/
mL) and 100 μl of dorsal horn lysate (50μg of protein) were run in duplicate following the
manufacturer instructions. Samples were read at 450 nm with wavelength correction at 540
nm. Samples were considered NRG1-β1 positive if the signal was higher than background
and within the range of the standard curve.
Primary microglia cell culture
Mixed glial cultures were isolated from cortex of P3 Wistar rats according to the method of
Giulian and Baker (Giulian and Baker, 1986). After mechanical and chemical dissociation
cells were seeded in DMEM with 10% FBS at a density of 500,000 cells/ml and cultured at
37°C in humidified 5% CO2/95% air. All reagents used were purchased from Invitrogen.
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Medium was replaced every 2–3 days and confluency was achieved after 5 days in vitro.
Confluent mixed glial cultures were manually shaken for 5 minutes and the floating cells
were pelleted and subcultured. After 15 minutes of plating the medium was change to
discharge all non adherent cells. This method resulted in 96-99% purity as assessed by Iba1
and DAPI staining. For proliferation assays GM-CSF (Granulocyte Monocyte Colony
Stimulating Factor, Cellsciences, 1nM) was used as a positive control (Giulian and Ingeman,
1988). Neuregulin β1 EGF domain (rHRGβ1 aa177-244 Genentech) was used
(0.5nM-10nM). NRG1, GM-CSF (1 nM) and negative control (only medium) were applied
in triplicate. For blocking the erbB2 receptor we used PD168393 at 2.5, 5 or 10μM or mAb
7.16.4 at 1, 2 or 4μg/mL. BrdU 10μM was administered 15 hours before fixation to label
proliferating cells.
Peritoneal macrophage preparation
Adult rats were killed with increasing CO2 concentrations and immediately after they were
injected intraperitoneally with 20mL of sterile HBBS. The elicited peritoneal exudates cells
were harvested and resuspended in DMEM supplemented or not with 10%FBS as required.
Cells were plated at a density of 300,000 cells/ml and cultured at 37°C in humidified 5%
CO2/95% air. For chemotaxis assays cells were used immediately after harvesting.
Chemotaxis assay
chemotaxis was assessed using the Boyden chamber (Neuroprobe, Bethesda, MD).
Polycarbonate filters (5 μm pore) were installed in the chamber, whose bottom wells were
filled with serum-free DMEM or NRG1 at various concentrations. Freshly prepared
microglia or macrophages were suspended in serum-free DMEM and were placed into the
top wells (50000 cells/well). The chamber was kept in a CO2 incubator at 37°C for 3 hours.
The filter was removed and stained with RapiDiffII (Biostain RRL,UK) The cells on the top
side of the filter were wiped off, and the number of cells that had migrated to the bottom
side were counted.
RT-PCR
was used for assessing mRNA expression of erbB receptors in microglial cultures. Total
RNA was isolated using an RNeasy Mini Kit (Qiagen) and first strand cDNA was reverse-
transcribed. The sequences for primers used in this study were: erbB2,
CCTGCCTCCACTTCAATCAT (forward), CAGGATCCCACTTCCGTAGA (reverse);
erbB3 TGAAGATGTGTGAGCCTTGC (forward), GGTCCAGTGCGGGTATCTTA
(reverse); erbB4 ATGGCCTTCCAACATGACTC (forward),
CACCTGCCATCACATTGTTC (reverse), (all 5′–3′). Amplification of templates was
detected using SYBR Green 1 dye (Roche, UK) on a Rotor-Gene thermal cycler (Corbett
Life Science). Melting curve analysis and sequencing confirmed specificity of the products.
PCR products were visualized in a 2% agarose gel.
Detection of IL-1β by ELISA
we used the Rat IL-1 beta/IL-1F2 Quantikine ELISA Kit (RLB00, R&D systems) which
mainly detects the mature or released form of IL1β. IL1β standards (31.2-2000 pg/ml) and
100μl of microglia culture supernates were run in duplicate following manufacturer
instructions. Samples were read at 450 nm with wavelength correction at 540 nm. Samples
were considered IL1β positive if the signal was higher than background and within the range
of the standard curve. The supernates of microglia were collected after the cells were primed
with LPS (1 μg/ml, Sigma for 3 hours) and treated with ATP (1mM, Sigma) or NRG1
(10nM) for 30 minutes.
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Western blots
Microglial and macrophages cultures or spinal cord dorsal horn were homogenized in lysate
buffer (20 mM Tris, pH 8, 137 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, and
protease inhibitor cocktail). The lysate were spun at 13,000 rpm at 4 °C for 15 minutes and
the protein concentration of supernatant was determined using a BCA Protein Assay kit
(Pierce, Rockford, IL). Proteins (50 μg/sample) were separated using 8% SDS-PAGE, and
transferred to nitrocellulose membranes. Membranes were then blocked in 10% skimmed
milk for 1 hour at room temperature and washed in PBS-T for three times at 5 minutes each.
Membranes were incubated with primary antibody, rabbit erbB2 (1:200), rabbit erbB3
(1:100) and rabbit erbB4 (1:200; all from Santa Cruz BT), overnight at 4°C. After several
PBS-T washes as described before, membranes were incubated with donkey anti-rabbit
HRP-conjugated secondary antibody (1:10,000; GE Healthcare) for 1 h at room temperature.
As a loading control we used mouse β-actin (1:10000, Sigma) and the secondary antibody
used was anti-mouse HRP-conjugated secondary antibody (1:10,000; GE Healthcare).
Membranes were revealed using ECL-plus reagent for 5 min (GE Healthcare) for detection
by autoradiography. Protein bands for all erbB receptors (185 kDa) and β-actin (42 kDa)
were quantified using a model GS-700 imaging densitometer (Bio-Rad Laboratories,
Hercules, CA). All quantifications were normalized against β-actin to ensure equal sample
loading.
Statistical analysis
Sample sizes for experiments were based on results from pilot studies. Data sets were tested
for normality using the Kolmogorov-Smirnov test and for homogeneity of variance using
Levene's Test. Parametric or non parametric tests were used accordingly. Behavioural data
was analysed using RM two way ANOVA. When the assumptions of sphericity were
violated (Mauchly's test; p<0.05) the Greenhouse-Geisser correction was applied. P<0.05
was considered as significant. Data are presented as mean ± SEM.
RESULTS
NRG1 promotes the survival, proliferation and chemotaxis of microglia
Using reverse transcriptase-mediated polymerase chain reaction (RT-PCR) analysis, we
found that cultured rat microglia express erbB2, 3 and 4 receptor mRNA and expression was
confirmed by immunocytochemistry and western blot analysis (Fig1). When microglial cells
are kept in serum free conditions, apoptotic cell death is observed within 24 hours (Koyama
et al., 2000). We found that NRG1 significantly promoted the survival of microglia which
had been cultured in such conditions for 72 hours (Fig 2 a-c). At NRG1 concentrations of
10nM the number of microglia was more than 5 times higher than seen in control (p=0.001,
one way ANOVA, 4 independent experiments). NRG1 application (10 nM) resulted in a
three fold reduction in the number of apoptotic microglial nuclei after 24 hours in serum free
conditions, as seen by Terminal deoxynucleotidyl transferase dUTP nick end labeled
staining (TUNEL) (p=0.008, one way ANOVA, 3 independent experiments fig 2 d-f). This
indicates that inhibition of apoptosis was responsible for the survival promoting effects of
NRG1. Because in many instances the erbB2 receptor is a key mediator of NRG1 signalling
we tested the consequences of erbB2 receptor blockade. We used either an irreversible
specific erbB inhibitor PD168393 (Bose et al., 2006) which blocks the ATP binding site of
the receptor, or the monoclonal antibody (mAb) 7.16.4 which specifically binds to the
extracellular domain of erbB2 (sharing antigenic epitopes with Herceptin®)(Katsumata et
al., 1995;Zhang et al., 1999). Both of these agents which themselves had no effect on cell
viability, could completely prevent the survival promoting effects of NRG1 in a dose
dependent manner (there was no significant difference comparing treatment with NRG1
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combined with PD168393 or mAb 7.16.4 and control, p=1, one way ANOVA, 3
independent experiments Fig 2 c, f, supplementary Fig 1).
We subsequently investigated the effects of NRG1 on microglial proliferation. In serum free
conditions we observed virtually no basal proliferation and very little response to either GM-
CSF or NRG1 (data not shown). Microglia were therefore cultured in medium supplemented
with 5% foetal bovine serum (FBS) and cell proliferation in response to NRG1 was
quantified using pulse labelling with BrdU. NRG1 treatment increased the proliferation of
microglia in a dose dependent manner (Figure 2 g,i) such that a dose of 10nM increased the
% of BrdU labelled nuclei from 11 to 60% (p<0.05, ANOVA on ranks, 3-4 independent
experiments). This effect was again dependent on activation of the erbB2 receptor as it could
be inhibited by PD168393 or mAb 7.16.4 in a dose dependent manner (both were not
significantly different from control, p=0.215 and p=0.516 for NRG1 plus PD168393 or mAb
7.16.4 respectively, t-tests, 3 independent experiments, supplementary Fig 1). The effect of
NRG1 was comparable to that elicited by GM-CSF a previously well described microglial
mitogen (Giulian and Ingeman, 1988).
Microglia are motile cells and demonstrate directed migration towards regions of injury.
Using a Boyden chamber in which microglia migrate through pores in a polycarbonate filter
across a concentration gradient, NRG1 was found to significantly increase microglial
chemotaxis in a dose dependant manner (Fig 2 j-l). A ‘chequerboard’ analysis (Martinet et
al., 1994) in which different concentrations of NRG1 were used in the upper and lower wells
was performed. This demonstrated that although there was migration when NRG1 was
added to both upper and lower wells in equal concentrations migration was greatest when
the concentration gradient between the lower and upper well was maximal (Fig 3). This is
consistent with a true chemotactic (ie. directed migration along a concentration gradient)
rather than solely a chemokinetic (ie. random migration) response produced by NRG1. The
chemotactic action of NRG1 was dose dependently inhibited by erbB2 receptor blockade
(NRG1 plus PD168393 or mAb 7.16.4, p=1 and p=0.36 versus control respectively, t-tests, 3
independent experiments, supplementary Fig 1). Note that neither of these erbB2 receptor
blocking agents had any effect on basal migration (PD168393 vs control p=0.3, mAb 7.16.4
vs. control p=0.6, Mann-Whitney Rank Sum Test). Microglia are closely related to tissue
macrophages and indeed we found that peritoneal macrophages also express erbB 2, 3 and 4
receptors and demonstrate enhanced motility in response to NRG1 (Supplementary Fig 2).
In response to CNS injury microglia adopt an effector (also termed activated) state which is
associated with development of an amoeboid morphology, pro-inflammatory cytokine
expression and expression of class 2 major histocompatibility complex (MHC-2) (Hanisch
and Kettenmann, 2007). NRG1 had no effect on Interleukin-1β (IL-1β) release from naïve
microglia however it significantly enhanced IL-1β release from microglia which had been
primed with lipopolysaccharide (LPS, a molecule known to activate microglia via the Toll-
like receptor 4 (Lehnardt et al., 2003), p<0.05 versus control, one way ANOVA on Ranks,
Fig 4). The administration of LPS results in process retraction and increased OX6
immunoreactivity (a marker of MHC-2 expression) of microglia. NRG1 however did not
elicit such changes (the percentage of OX6 immunoreactivity in LPS-treated cells was 5
times higher than in the control p<0.001, the NRG1-treated cells were no different from
control p=1, one way ANOVA, 3 independent experiments) (Fig 4).
Intrathecal NRG1 produces dorsal horn microgliosis associated with mechanical and cold
pain related hypersensitivity
To investigate the effects of NRG1 on microglia in vivo we administered this molecule
intrathecally (0.4 or 4 ng given daily for 3 days), following which we assessed both the
response of dorsal horn microglia as well as pain related behaviour. Intrathecal NRG1
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produced a dose dependent increase in the number of microglia within the lumbar dorsal
horn and many of these cells were noted to develop an activated morphology with
hypertrophy of the cell body and process retraction (Fig 5a-c). Although a significant dorsal
horn microgliosis was observed at day 1 (0.4 or 4 ng versus control p=0.02 and p=0.002
respectively, one way ANOVA, n=4 per group) it was much more apparent at day 3 (Fig 5a-
c, 0.4 and 4 ng versus control p<0.05, ANOVA on Ranks, n=4). Furthermore, the number of
microglia undergoing proliferation as assessed by pulse labelling with BrdU also
significantly increased (Fig 5d-l, p<0.05 4ng versus control, ANOVA on Ranks, n=4 per
group). The microglial response within the dorsal horn following NRG1 treatment was
mirrored by the development of a dose dependent mechanical and cold pain related
hypersensitivity (Fig 5m p=0.009 and p<0.001 at day 1 and 3 respectively for 4ng vs
control; p=0.04 for 0.4ng vs control at day 3. Fig 5n p<0.001 for 4ng vs control at day 3,
RM 2 way ANOVA, n=7-8 per group). As with the morphological changes in microglia pain
related hypersensitivity was much more marked at day 3 than at day 1.
ErbB2 receptor inhibition or sequestration of endogenous NRG reduces microgliosis
following peripheral nerve injury
We next explored the role of NRG1-erbB signalling in microglia in a nerve injury model (L5
Spinal Nerve Ligation (Kim and Chung, 1992)) which results in a robust microgliosis. To
visualize the location of erbB2 in its activated state a phosphorylation state specific antibody
was used (Guertin et al., 2005). Following L5 SNL a significant increase in expression of
the phosphorylated (i.e. activated) form of erbB2 receptor was seen in the ipsilateral dorsal
horn of the spinal cord (Fig 6 a). No immunostaining was observed following pre-incubation
of the antibody with the peptide used as the immunogen. Phospho-erbB2 expression was
entirely restricted to microglia; phospho-erbB2 co-localized with the microglial markers
Iba-1 (ionized calcium binding adaptor molecule 1) and OX-42 (which recognizes
complement receptor type 3). Of 518 phospo-erbB2 positive cells counted 99% co-
expressed Iba-1. There was no co-localization with either the neuronal marker neuronal-
specific nuclear protein (NeuN) or the astrocyte marker Glial Fibrillary Acidic Protein
(GFAP) (Fig 6 b-g). The time course of p-erbB2 expression, which was maximal at days
3-7, closely mirrored the temporal profile of the development of microgliosis (Figure 7 d-h).
Using Western Blot analysis we saw a significant increase in erbB3 receptor expression in
the dorsal horn following SNL. No change was observed in erbB2 and erbB4 expression
(p=0.02 naïve vs day 3 after SNL for erbB3, p= 0.34 and p=1 for erbB2 and erbB4
respectively, Mann-Whitney Rank Sum Test, n=4, supplementary Figure 3).
The principal isoforms of NRG1 expressed within the nervous system are those with a β
EGF domain ((Meyer and Birchmeier, 1994; Shinoda et al., 1997). To identify cells
expressing NRG1 in the adult we used an oligonucleotide probe which recognises a
sequence common to all β isoforms (Fricker et al., 2009). In dorsal root ganglia as
previously noted β EGF mRNA is expressed by both small diameter (identified through the
expression of the neuropeptide CGRP or binding of Isolectin B4) and large diameter
(identified by the expression of phosphoylated neurofilament heavy chain-NF200) DRG
cells. Expression was highest in large diameter DRG cells consistent with the high level of
expression of the type III β NRG isoform in these cells. In the naïve situation 67 ±3.7 % of
DRG cells expressed β EGF mRNA and at 3 days post SNL (when microgliosis is well
established) 62 ±1 % of DRG cells expressed β EGF mRNA (Figure 8a-f). This probe
demonstrated neuronal expression within the spinal cord particularly in motoneurons and
occasional neurons in the deeper laminae of the dorsal horn (data not shown). We did not
see expression in astrocytes either in the naïve state or after injury. The most likely source of
NRG within the dorsal horn is therefore likely to be primary afferent terminals.
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The H 210 antibody that recognises the N terminus of NRG1 was used to localise NRG1
immunoreactivity. To confirm antibody specificity tissue from mice with conditional NRG1
gene ablation in sensory neurons was used (mice expressing Cre under control elements of
the neurofilament heavy chain gene NFH-Cre (Mallucci et al., 2002) were crossed with mice
with loxp sites flanking the essential EGF domain of NRG1 (NRG fl/fl) Yang et al., 2001). In
NFH Cre; NRG1 fl/fl mice NRG1 is ablated in sensory neurons in the late embryonic period
resulting in a severe dysmyelinating neuropathy and shortened survival (DLHB unpublished
observations). Note that normal NRG1 immunoreactivity is observed in DRG cells of
NRG fl/fl (ie. control) animals while no immunoreactivity is present DRG cells of NFH Cre
NRG1 fl/fl animals. (Figure 8 g-h). NRG1 immunoreactivity was observed within DRG cells
of all cell sizes (in naïve situation: 61.9 ± 1.2 % of all cells were positive, at 3 days after
SNL: 58.4 ± 2.1 %, figure 8 i-j). NRG1 immunoreactivity was also seen within the dorsal
horn of the spinal cord (especially within superficial laminae, Figure 8k) and this increased
at 3 days post SNL (ipsilateral to lesion). An ELISA which recognises NRG1 isoforms
containing β EGF and IgG domains demonstrated a significant increase in the level of this
protein within the dorsal horn at 3 days post SNL (Figure 8l, p=0.04, one way ANOVA
Bonferroni post hoc test, n=3 per group).
To test whether activation of the erbB2 receptor contributes to microgliosis in vivo we
inhibited it using PD168393, the erbB2 receptor blocking antibodies mAb7.16.4 (discussed
above) or mAb-9 (B10) which causes erbB2 homodimerization without activation of
downstream signalling pathways and accelerates receptor endocytosis (Pugatsch et al.,
2006;Sawyer et al., 2002). At day 3 following SNL, when the microglial response is well
established, we found that blocking the erbB2 receptor could dose dependently reduce the
number of microglia within the ipsilateral dorsal horn with an activated morphology (using
PD168393 5 μg/day i.t. infusion (p=0.002), mAb7.16.4 5μg i.t. injection (p<0.001) or
mAb-9 5μg i.t. injection (p<0.001) respectively compared to control, one way ANOVA,
n=3-4 per group, Fig 9 a-c, supplemental figure 1d). The number of microglia within the
dorsal horn which were phospho-p38 MAPK positive was also significantly reduced
following erbB2 inhibition (p<0.001, following treatment with PD168393 5 μg/day i.t.
infusion, mAb7.16.4 5μg i.t. injection, or mAb-9 5μg i.t. injection compared to control, one
way ANOVA, n=3-4 per group, Fig 9 f-j).
To sequester endogenous NRG we used a fusion protein (HBD-S-H4) consisting of the
soluble ectodomain of erbB4 which has high affinity for NRG and a heparin binding domain
which helps target the molecule to the same heparan-sulfate rich cell surfaces which bind
NRG. This has been shown to be highly effective in vitro and blocks the survival promoting
activity of NRG on Schwann cells in vivo (Ma et al., 2009). Intrathecal administration of
HBD-S-H4 (3 μg, i.t. injection) significantly reduced both the number of microglia with an
activated morphology within the dorsal horn and phospho-p38 expression following SNL (in
both cases p<0.01, following treatment with HBD-S-H4 versus control, unpaired t-test,
n=3-4 per group, Figure 9).
Pulse labelling with BrdU showed a marked increase in the rate of cell proliferation within
the dorsal horn of the spinal cord following SNL and, as previously reported (Echeverry et
al., 2008), the vast majority of these cells (94.6 ± 1.2 %) were microglia. The number of
proliferating microglia within the dorsal horn was reduced by approximately 60-70%
following blockade of erbB2 (p<0.001, following treatment with PD168393 (5 μg/day i.t.
infusion), mAb7.16.4 (5 μg/day i.t. infusion), or mAb-9 (5 μg/day i.t. infusion) compared to
control, one way ANOVA, n=3-4 per group, Figure 10).
Inhibition of erbB2 significantly reduced the number of microglia with activated
morphology, expression of phospho-p38 MAPK and microglial proliferation at a later time
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point following nerve injury ie. 7 days post SNL (Supplementary Fig 4). In a further set of
experiments we assessed dorsal horn microgliosis at 7 days following pump emptying (ie.
21 days post SNL). We found no significant difference in dorsal horn microgliosis at this
time point comparing intrathecal treatment with PD168393 and control (p=0.57, t-test,
n=3-4, Supplementary Fig 5). Neuregulin is known to have a key role in signalling between
axons and Schwann cells in peripheral nervous system (Chen et al., 2003; Fricker et al.,
2009; Nave and Salzer 2006). There is therefore the theoretical possibility that these changes
could be secondary to changes in axoglial signalling in the periphery if the inhibitor or
antibody were to spread outside of the intrathecal space. To exclude this possibility we
administered mAb7.16.4 directly to the site of spinal nerve ligation and found that in
contrast to intrathecal treatment this peripheral administration had no effect on dorsal horn
microgliosis (p=0.18, t-test, n=3-4, Supplementary Fig 6).
A week following SNL we observed a significant increase in astrocytes within the ipsilateral
spinal cord (p=0.004, t-test, n=4), which is in accordance with previous reports of a delayed
astrocytosis following nerve injury (Colburn et al., 1999). However, unlike the microgliosis
this was not reduced by erbB2 inhibition (p=0.88, t-test, n=4, Supplementary Fig 7).
ErbB2 receptor inhibition or sequestration of endogenous NRG reduces mechanical and
cold pain related hypersensitivity following nerve injury
There is increasing evidence that the microglial activation observed within the dorsal horn of
the spinal cord following nerve injury contributes to the development of neuropathic pain
(Tsuda et al., 2003;Milligan and Watkins, 2009). Intrathecal infusion of PD168393 over 7
days had no effect on mechanical withdrawal thresholds in naïve animals (p=0.25, RM 2
way ANOVA, PD168393 5μg/day versus vehicle, data not shown). We therefore monitored
pain related behaviour over 14 days following L5 SNL in animals which were treated with
the erbB2 inhibitor or vehicle delivered via continuous intrathecal infusion. In both groups
of animals a clear mechanical hypersensitivity was observed at day 1 following SNL
however at subsequent time points erbB2 receptor inhibition resulted in a significant dose
dependent reduction in mechanical pain hypersensitivity on the side ipsilateral to the lesion
(Fig 11a, p<0.05, RM 2 way ANOVA, PD168393 10 or 5 μg day versus vehicle n=7-11/
group) with no effect on the contralateral paw (data not shown). Once the pump had emptied
the mechanical withdrawal thresholds of the group receiving PD168393 5μg/day returned to
those of control (Fig 11b). Delayed treatment with PD168393 5μg/day from day 3 onwards
(by which time microgliosis is well established) was not effective at reversing mechanical
pain related hypersensitivity (Fig 11c, p=0.75 RM 2 way ANOVA, n=7 per group). Cold
allodynia (as assessed by nociceptive behaviour in response to acetone application to the
paw) also developed following SNL and was significantly attenuated in a dose dependent
fashion by erbB2 inhibition (Fig 11d p<0.05 PD168393 10 or 5 μg day versus vehicle RM 2
way ANOVA, n=7-11/group). Intrathecal injection of HBD-S-H4 (two 3μg i.t. injections
administered on the day of surgery and on day 3 post surgery) which sequesters endogenous
NRG also significantly attenuated mechanical pain related hypersensitivity (Fig 11e,
p<0.001 versus control, RM 2 way ANOVA, n=8 per group) and cold allodynia (Fig 11f,
p<0.05 versus control, RM 2 way ANOVA, n=8 per group).
Discussion
Microglia closely resemble tissue macrophages and are key sensors of injury to the central
nervous system produced by many diverse pathologies. NRG1 has not previously been
implicated in regulating microglial function. Here we demonstrate that NRG1 is a survival,
proliferative and chemotactic factor for microglia in vitro and that NRG1-erbB signalling is
activated specifically within microglia following peripheral nerve injury contributing to the
development of microgliosis and consequently neuropathic pain.
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Microglia, express the NRG1 receptors erbB2, 3 and 4. This factor promotes the survival of
microglia in vitro through inhibition of apoptosis and is a potent proliferative factor for these
cells in an erbB2 dependent manner. In addition to proliferation the other means by which
microglia can accumulate at the site of injury is through directed migration in response to
the release of chemotactic agents which include: purines (Honda et al., 2001) complement
components (Yao et al., 1990), bradykinin (Ifuku et al., 2007) and chemokines (Peterson et
al., 1997). We have used the Boyden chamber chemotaxis assay and by manipulating the
concentration gradient in the upper and lower wells have shown that NRG1 is a chemotactic
agent for microglia acting in an erbB2 dependent manner. Neuregulin has previously been
shown to increase motility of a number of different cell types including malignant cell lines
(Hijazi et al., 2000) keratinocytes (Schelfhout et al., 2002) and Schwann cells (Lyons et al.,
2005). NRG1 could also enhance the release of interleukin-1ß from LPS primed microglia.
Unlike LPS however NRG1 application did not promote the development of amoeboid
morphology or MHC class II expression in microglia. We have found that macrophages
express erbB2, 3 and 4 receptors. Therefore, in situations where there is major disruption of
the blood brain barrier (such as traumatic brain injury) resulting in macrophage infiltration
into the CNS the function of macrophages may also be modulated by NRG1.
Because of the potent effects we observed of NRG1 on cultured microglia we explored the
relevance of this signalling pathway in vivo. Intrathecal administration of NRG1 resulted in
a dorsal horn microgliosis and also produced mechanical and cold pain related
hypersensitivity (in agreement with a previous study, Lacroix-Fralish et al., 2008). Spinal
nerve ligation provides a well characterized model of nerve injury associated with a robust
microgliosis (Scholz and Woolf, 2007; Tsuda et al., 2003) and the development of
neuropathic pain (Kim and Chung, 1992). We used an antibody which recognizes
phosphorylated erbB2 as a measure of receptor activation (Guertin et al., 2005). In naïve and
sham surgery animals there was only a low level of p-erbB2 expression in resting microglia.
Following SNL p-erbB2 expression increased and it was localized specifically within
microglia especially those with an activated morphology. The time course of p-erbB2
expression within the dorsal horn was coincident with the development of microgliosis
being detectable at day1 after injury and peaking at day 3-7 post SNL.
For NRG1 to act as a proliferative and chemotactic agent for microglia it needs to be
released at the site of injury. All NRG1 isoforms contain an EGF domain which is required
for biological activity and can be classified into sub groups according to the structure of
their amino termini. Type I and II isoforms have Ig like domains and can either be directly
secreted or alternatively transmembrane isoforms undergo metalloprotease mediated
cleavage to be released as soluble proteins from the cell surface. These isoforms bind avidly
to the extracellular matrix which can act as a source of localized release (Loeb and
Fischbach, 1995). Type III isoforms possess a cysteine-rich domain (CRD) and undergo
proteolytic cleavage by BACE (Willem et al., 2006) however, the EGF domain remains
membrane tethered and so this molecule signals in a juxtacrine fashion. DRG cells have
been reported to principally express type I and III isoforms (Bermingham-McDonogh et al.,
1997). We found clear expression of NRG1 by small and large diameter DRG cells using in
situ hybridization and a probe that recognises all β EGF isoforms (the nervous system
principally expresses beta rather than alpha isoforms). β EGF mRNA was expressed at low
levels by occasional dorsal horn neurons and so we propose that the most likely source of
NRG1 within the dorsal horn is from primary afferent terminals. We did not observe a
change in β EGF mRNA expression in DRG cells or the dorsal horn at 3 days following
SNL a time point when microgliosis is well established. We did find significantly increased
β EGF containing NRG1 protein within the dorsal horn using an ELISA following SNL.
Cultured neurons have been shown to release soluble NRG1 in an activity dependent manner
(Ozaki et al., 2004) and NRG1 activity has also been detected in human cerebrospinal fluid
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(Pankonin et al., 2009). In culture systems NRG1 activity has also been shown to be
released from DRG cell axons (Esper and Loeb, 2004; Taveggia et al., 2005); this release is
enhanced by BDNF (which is itself released by microglia following nerve injury (Coull et
al., 2005)). The rapid response of microglia following SNL suggest that increased NRG1
activity within the dorsal horn following nerve injury is due to either: altered NRG1 protein
trafficking or release from primary afferent terminals or possibly release from the
extracellular matrix. We suggest that such NRG1 release provides an injury related signal
from primary afferents triggering a microglial response within the dorsal horn.
We tested the hypothesis that inhibition of NRG-erbB signalling would reduce the
microgliosis produced by SNL. We used two strategies for erbB2 receptor inhibition:
intrathecal treatment with either an irreversible specific erbB inhibitor (PD168393) which
blocks the ATP binding site of the receptor or monoclonal antibodies (mAb 7.16.4 and
mAb-9). MAb 7.16.4 specifically binds to the extracellular domain of erbB2, down regulates
surface expression of erbB2 and blocks activation of erbB2/3 and erbB2/4 heterodimers; this
antibody has previously been shown to have efficacy in vivo (Yarden and Sliwkowski,
2001; Katsumata et al., 1995). Inhibition of the erbB2 receptor following nerve injury
resulted in a significant reduction in the microgliosis within the dorsal horn as well as
reducing the expression of Phospho-p38 (a component of the mitogen-activated protein
kinase (MAPK) signalling cascade) which is specifically expressed within activated
microglia (Jin et al., 2003;Kobayashi et al., 2008). This effect on p38 signaling is likely to
be indirect as NRG1 did not stimulate the p38 MAPK pathway in cultured microglia
although it does activate the MEK-ERK and PI-3 kinase-AKT pathways (MC, NZ and DB
unpublished observations). Interestingly ERK has previously been shown to be activated in
microglia following peripheral nerve injury (Zhuang et al., 2005). We have also employed a
molecule (HBD-S-H4) to sequester endogenous NRG1. This is a fusion protein consisting of
the soluble ectodomain of erbB4 which has high affinity for NRG1 and a heparin binding
domain which helps target the molecule to the same heparan-sulfate rich cell surfaces which
bind NRG1. This molecule could also effectively reduce dorsal horn microgliosis and pp38
expression following SNL.
Given the lack of major disruption to the blood brain barrier following SNL (Abram et al.,
2006;Lu et al., 2009) proliferation of resident microglia is likely to be the principal means
by which microglial numbers increase following SNL. We found a clear increase in
microglial cell proliferation within the dorsal horn in the first 3 days following peripheral
nerve injury. ErbB2 receptor blockade significantly reduced this proliferative response.
Inhibition of microglial proliferation provides one explanation for the reduction in
microgliosis observed following erbB2 receptor inhibition although impaired chemotaxis of
local microglia may also play a role. ErbB2 inhibition specifically reduced microgliosis
following nerve injury and did not prevent the development of astrocytosis.
There is now increasing evidence that glial cells (both microglia and astrocytes) play an
important role in the generation of neuropathic pain. A number of molecules have been
implicated in the recruitment and activation of microglia within the dorsal horn following
nerve injury including cytokines, chemokines (such as CCL2 and Fractalkine), complement
components and purines (Milligan and Watkins, 2009;Scholz and Woolf, 2007;Tsuda et al.,
2003;Clark et al., 2007;Thacker et al., 2009;Zhang et al., 2007;Jin et al., 2003). Following
activation microglia release cytokines and BDNF which enhance the excitability of dorsal
horn neurons (Coull et al., 2005; Kawasaki et al., 2008). Inhibition of the microglial
response to injury has been shown to effectively reduce the development of neuropathic pain
(Tsuda et al., 2003;Coull et al., 2005;Ledeboer et al., 2005;Clark et al., 2007). ErbB2
receptor inhibition or sequestration of endogenous NRG1 could ameliorate (but not
completely reverse) both mechanical and cold pain related hypersensitivity following SNL.
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Following peripheral nerve injury the pro-inflammatory microglial response is clearly
deleterious as it contributes to neuropathic pain however in other contexts there is evidence
that these cells may be neuroprotective (Hanisch and Kettenmann, 2007). NRG-erbB
signalling represents a novel pathway stimulating microglial proliferation and chemotaxis.
We have shown that this contributes to the development neuropathic pain and it will be of
great interest in the future to determine the role of NRG-erbB signalling in mediating the
microglial response to other forms of CNS injury.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. erbB receptor expression in primary cultured microglia
a.Using reverse transcriptase-mediated polymerase chain reaction (RT-PCR) analysis we
found that primary cultured rat microglia express the erbB2, 3 and 4 receptors. 2% agarose
gels stained with ethidium bromide and photographed under ultraviolet light are shown for
the PCR products of each of the genes amplified. Pos= positive control (E16 embryonic rat
brain cDNA), MG= microglia, Neg= Negative control (water). b. ErbB receptors expression
is shown in microglial cells by IHC (IB4 labels microglia green, the erbB receptors are in
red, scale bar: 20μm). c. Western blot analysis showing a 185 kDa band for erbB2, 3 and 4
in lysates from microglial cells.
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Figure 2. NRG1 stimulates microglial survival, proliferation and chemotaxis in vitro
a-c Survival of microglia in vitro was assessed by incubating cultured microglia for 3 days
in serum-free medium which was supplemented with increasing doses of NRG1 (0.5-10nM
or GM-CSF 1nM (as a positive control). Representative wells are shown in which microglia
are identified by Iba1 immunostaining following no treatment (a) or addition of 10nM
NRG1 (b). NRG1 promoted microglial survival and erbB2 inhibition using PD168393 (INH,
10μM) or mAb 7.16.4 (AB, 4μg/ml) blocked this effect. Quantification of microglial
numbers is shown in (c) d-f Cultured microglia were incubated for one day in serum-free
medium with (e) or without (d) the addition of NRG1. DAPI staining (blue) demonstrated
nuclei and TUNEL labeling (yellow) revealed those undergoing apoptosis. Treatment with
NRG1 (10nM) significantly decreased apoptosis, an effect which was prevented when
microglia were treated with the erbB inhibitor PD168393 in combination with NRG1. g-i
Proliferation was assessed by incubating microglia in medium supplemented with 5% FBS
for 3 days and pulse-labeling with BrdU (yellow). NRG1 treatment significantly increased
the proportion of BrdU-positive microglial nuclei, an effect that was erbB2 dependant. j-l:
The effects of NRG1 on microglial migration was studied using a Boyden chamber. The
addition of NRG1 to the lower well of the chamber (k) increased microglial migration to the
inner membrane surface compared to control (j). Inhibition of erbB2 blocked this action.
Scale bars: 100μm. Error bars represent ± SEM (3-5 independent experiments). The
statistical tests used were one way ANOVA with Bonferroni post hoc analysis for all
comparisons except for the proliferation experiment in which the data was not normally
distributed and ANOVA on ranks with Dunn's post hoc test was used instead. ** p <0.005, *
p <0.05. (CON: control, INH: inhibitor (PD168393), AB: neutralizing antibody (7.16.4).)
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Figure 3. The migration of microglial cells in response to NRG1 is a true chemotactic response
In a Boyden chamber microglial cells migrate from an upper to a lower well through a
polycarbonate filter in response to a concentration gradient of the putative chemotactic
agent. A ‘chequerboard’ analysis of 3 independent experiments assessing the chemotactic
response to NRG1 performed in triplicate and normalized to the unstimulated control is
shown. Microglial cells were suspended in medium alone or with 0.1, 1 or 10 nM NRG1 and
then allowed to migrate for 3 hours at 37°C towards different concentrations of NRG1 in the
lower compartments. Highlighted in grey boxes are the results achieved by using the same
concentration of NRG1 in upper and lower wells. Note that in this circumstance NRG1
increases microglial migration indicating chemokinesis. When there is an increasing
concentration gradient from the upper to lower well (values in grey) migration is clearly
enhanced indicating a true chemotactic response. (*p<0.05 comparing migration across a
gradient versus migration when the NRG1 concentration is the same in both wells) Numbers
represent the mean ± SEM.
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Figure 4. NRG1 promotes the release of Il-1β from LPS primed microglia but does not stimulate
MHC-2 expression
a. An ELISA was used to quantify IL-1β released into the medium of cultured microglia.
Neither ATP (1mM) nor NRG1 (10nM) alone produced Il-1β release from naïve microglia
however both significantly promoted Il-1β release from LPS (1 μg/ml) primed microglia in
a dose dependent manner. (Error bars represent ± SEM, Statistical test: ANOVA on Ranks,
*p<0.05, n=3).
b. Another aspect of the activation (or effector) response of microglia is that they increase
expression of MHC-2. To investigate wherever NRG1 treatment leads to such a response in
microglia we incubated primary cultures in serum-free medium and treated them with
lipopolysaccharide (LPS 1 μg/ml), NRG1 (10nM) or medium alone (CON). Microglia were
immunostained with OX-6 (which labels MHC-2), Iba1 (microglial marker) and DAPI
(nuclear staining). LPS treatment led to a 5-fold increase in OX-6 expression compared with
control (p<0.001), whilst NRG1 treatment didn't elicit such a response (p=1). Treatment
with LPS also resulted in microglia adopting an amoeboid morphology unlike NRG1. Scale
bars: 100 μm. Error bars represent ± SEM (3 independent experiments) Statistical test: one
way ANOVA, Bonferroni post hoc analysis. **p<0.001
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Figure 5. Intrathecal administration of NRG1 results in dorsal horn microgliosis associated with
mechanical and cold pain related hypersensitivity
NRG1β was administered intrathecally (0.4 or 4 ng given daily for 3 days) a-b Dorsal horn
of animals treated with saline (control in a) or NRG1 (4 ng in b) 3 days after the first
injection, immunostained with Iba1. Note the increase in numbers of microglia with an
activated morphology. c is shows quantification of this response at 1 and 3 days after NRG1
injections (*p<0.05, **p<0.001 comparing NRG1 doses vs control). In d-l we assessed
proliferation (pulse labelling with BrdU) after NRG1 injections (Iba1 is shown in red, BrdU
in green, DAPI in blue and in the last panel merged images are shown). D-g dorsal horn
microglia from a saline treated animal (note that no BrdU is present). H-k dorsal horn
microglia from a NRG1 (4 ng) treated animal. In l is shown the quantification of all BrdU
positive microglia in the dorsal horn of all groups at day 1 and day 3 after injections were
started (*p<0.05 comparing 4ng versus control). Mechanical (shown in m) and cold (shown
in n) pain related hypersensitivity developed after NRG1 injections in a dose dependant
manner (*p<0.05, **p<0.001 for 4ng versus control; #p<0.05 for 0.4ng versus control).
Scale bars: a-b: 100μm, d-k: 10 μm.
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Figure 6. Peripheral nerve injury leads to increased phospho-erbB2 expression within dorsal
horn microglia
Three days after L5 SNL, the expression of the phosphorylated form of the erbB2 receptor
was increased in the ipsilateral dorsal horn (a). Phospho-erbB2 immunostaining (green) co-
localized with Iba1 (microglial marker in red in b), but not with GFAP (astrocyte marker in
red, c) or NeuN (neuronal marker in red, d). P-erbB2 (green in e) also co-localized with
OX-42 (a marker of activated microglia red, f). Scale bars: 200 μm (a), 50 μm (b-d), 10 μm
(e-g)
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Figure 7. The time course of phospho-erbB2 expression is coincident with the development of
microgliosis
The microglial response to nerve injury develops during the first week following injury,
(demonstrated by immunostaining with the microglial marker Iba1) (a-c). An increase in
microglial numbers is observed in the ipsilateral dorsal and ventral horn of the spinal cord of
L5 SNL animals (a). A closer view shows that microglia change their morphology from
having long processes and a small soma (b, naïve animal, termed surveying microglia) to
having retracted processes and a hypertrophic soma (c, 3 days after L5 SNL termed an
effector or activated morphology). Simultaneous with this microgliosis we observed an
increased expression of the p-erbB2 receptor (green) in the ipsilateral dorsal horn microglia
(labeled with Iba1 in red). d: naive, e: 1 day after SNL, f: 3 days after SNL, g: 21 days after
SNL. There was a significant increase in both total microglial number and the proportion
which were p-erbB2 positive within the dorsal horn following nerve injury, * p<0.05 (n:
3-4), one way ANOVA on ranks, post hoc Student-Newman-Keuls Method) Scale bars: 200
μm (a), 10 μm (b-c), 100 μm (d-g)
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Figure 8. NRG1 expression after L5 Spinal Nerve Ligation
ISH: a-f In-situ hybridisation images using a probe directed against the βEGF domain of
NRG1 in L5 DRG of naïve animals (a-c) and 3 days post SNL (d-f). Expression is highest in
large diameter DRG cells positive for NF 200 (green) but is also observed in small DRG
cells positive for either IB4 (blue) or CGRP (red). Arrows provide illustrative examples of
double labelled cells. There was no significant change in the proportion of DRG cells
expressing EGF mRNA at 3 days post SNL.
IHC: g-h. We used the H210 antibody which is raised against the N-terminal extracellular
domain of NRG1. To confirm specificity we tested it in NRG1 knock out tissue (NFH Cre
NRG1 fl/fl mice in which NRG1 is ablated in sensory neurons in the late embryonic period)
Note that normal NRG1 immunoreactivity is observed in DRG cells of NRG fl/fl mice (ie.
control) while no immunoreactivity is present DRG cells of NFH Cre NRG1 fl/fl mice. i-k
Immunohistochemistry confirmed that NRG1 was present in around 60% of DRG cells (i-j)
and within the dorsal horn of the spinal cord (especially within superficial laminae, k).
NRG1 expression was also assessed using a NRG1β specific ELISA (l). Lysate from dorsal
horn spinal cord of naïve,1 day and 3 days after SNL animals were run (50 ug of protein for
each sample). All sample values were within the range of the ELISA detection. A significant
increase in NRG1 was detected at 3 days after SNL (p=0.04, one way ANOVA, Bonferroni
post hoc test, n=3) Scale bars: a-h: 50μm, i: 200 μm.
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Figure 9. ErbB2 receptor blockade or sequestration of endogenous NRG inhibits the
development of microgliosis following spinal nerve ligation
The effect of erbB2 receptor blockers (PD168393, 5 μg/day i.t. or monoclonal antibodies
mAb-9 or 7.16.4, 5 μg i.t.) or a NRG sequestering molecule (HBD-S-H4, 3μg i.t.) was
determined at 3 days post SNL. a-e ErbB2 receptor blockade (b and e low and high power
photomicrographs respectively) resulted in a reduction in both p-erbB2 (green) expression
and in the number of microglia in the dorsal horn (Iba1 immunostaining, red) compared with
vehicle (a and d low and high power photomicrographs respectively). Quantification (c)
demonstrates that SNL results in an increased number of microglia with activated
morphology compared to sham surgery animals. This increase was significantly attenuated
following treatment with either: erbB2 inhibitor, erbB2 receptor blocking antibodies or the
NRG1 antagonist (HBD-S-H4) with respect to control. f-j SNL results in increased numbers
of microglia expressing phospho-p38. The number of microglia (red) expressing p-p38
MAPK (green) post SNL was significantly reduced following erbB2 receptor blockade or
sequestration of NRG using HBD-S-H4. Quantification in h. Scale bars for a-b and f-g: 100
μm, scale bars for d-e and i-j: 50μm.. Error bars represent ± SEM (n: 3-4 per group). SH:
sham, VH: vehicle, INH: inhibitor (PD168393), IgG2a: non immune IgG (control), ANT:
antagonist (HBD-S-H4). Statistical test: t-test (vehicle vs inhibitor and control vs antagonist)
or one way ANOVA, Bonferroni post hoc (IgG2a vs erbB2 receptor blocking
antibodies).**p<0.005. Scale bars:
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Figure 10. Microglial proliferation after spinal nerve ligation is significantly reduced following
erbB2 receptor inhibition
Three days after L5 SNL a proliferative response is seen in microglia within the dorsal horn
as shown here by labelling newly dividing cells with BrdU (yellow) and microglia with Iba1
(red). DAPI is shown in blue to delineate nuclei. The BrdU labeled nuclei are almost
exclusively within microglial cells (as seen in the merge image). Blocking the erbB2
receptor with PD168393 (5 μg/day i.t.) or with the blocking antibodies (mAb-9 or 7.16.4, 5
μg i.t.) resulted in a significant reduction in microglial proliferation. Scale bar: 100μm.
Error bars represent ± SEM (n 3-4 per group). SH: sham, VH: vehicle, INH: inhibitor
(PD168393), IgG2a: non immune IgG (control). Statistical test: one way ANOVA,
Bonferroni post hoc.**p<0.005
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Figure 11. erbB2 receptor inhibition or sequestration of endogenous NRG reduced mechanical
pain hypersensitivity and cold allodynia following spinal nerve ligation
Animals underwent L5 SNL and received a continuous intrathecal infusion of the erbB2
inhibitor (PD168393, 1.25-10 μg/day) or vehicle for 14 days. a: Mechanical hypersensitivity
developed at day 1 after SNL in both groups and after day 2 was significantly attenuated in
animals receiving the erbB2 inhibitor in a dose dependent fashion (**p<0.001, *p<0.05 for
10 μg/day versus vehicle, # p<0.05 for 5 μg/day versus vehicle, n=7-11/group) b: Once the
pump had emptied the withdrawal thresholds of the group receiving the erbB2 inhibitor (5
μg/day) returned to those of control. c: Delayed treatment with the erbB2 inhibitor (5 μg/
day) from day 3 onwards (by which time microgliosis is well established) was not effective
at reversing mechanical pain related hypersensitivity (p=0.75) d: Cold allodynia was also
significantly reduced in a dose dependent fashion by inhibiting the erbB2 receptor
(**p<0.001 for 10 μg/day versus vehicle, # p<0.05 for 5 μg/day versus vehicle, n=7-11/
group). e and f: Intrathecal administration of HBD-S-H4 (3 μg) at day 0 and 4 post SNL
(shown by arrows) significantly reduced mechanical (p<0.001) (e) and cold (p<0.05)(f) pain
related hypersensitivity. Error bars represent ±SEM. Statistical tests: two way ANOVA,
Bonferroni or Fischer LSD post hoc analysis. When the assumptions of sphericity were
violated (Mauchly's test; p<0.05) the Greenhouse-Geisser correction was applied and
independent two-tailed t-tests were used to determine differences between groups. INH:
inhibitor (PD168393), Nrg ANT: NRG antagonist (HBD-S-H4). The lines in a-d denote the
period of pump infusion. The arrows in e-f denote the days of i.t. injections.
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